814 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
What's in Store for Healthcare ETFs in Q3 Earnings? http://www.zacks.com/stock/news/575582/whats-in-store-for-healthcare-etfs-in-q3-earnings?cid=CS-ZC-FT-etf_news_and_commentary-575582 Oct 21, 2019 - With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Alexion Gets FDA Approval for Label Expansion of Ultomiris http://www.zacks.com/stock/news/575533/alexion-gets-fda-approval-for-label-expansion-of-ultomiris?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-575533 Oct 21, 2019 - Alexion (ALXN) obtains FDA approval for the label expansion of Ultomiris for the treatment of ultra-rare disease, aHUS.
Will Soliris Aid Growth for Alexion (ALXN) in Q3 Earnings? http://www.zacks.com/stock/news/571486/will-soliris-aid-growth-for-alexion-alxn-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-571486 Oct 18, 2019 - During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
Alexion to Buy Achillion for $930M, Strengthen PNH Franchise http://www.zacks.com/stock/news/570798/alexion-to-buy-achillion-for-%24930m-strengthen-pnh-franchise?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-570798 Oct 18, 2019 - Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.
Roche Posts Solid Sales for First 9 Months of '19, Ups View http://www.zacks.com/stock/news/569605/roche-posts-solid-sales-for-first-9-months-of-19-ups-view?cid=CS-ZC-FT-analyst_blog|earnings_article-569605 Oct 17, 2019 - Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings? http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-569574 Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Lilly Gets FDA Approval for New Oral Tablets for Migraine http://www.zacks.com/stock/news/563662/lilly-gets-fda-approval-for-new-oral-tablets-for-migraine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563662 Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Roche Announces Positive Late-Stage Data on Rituxan in PV http://www.zacks.com/stock/news/563858/roche-announces-positive-late-stage-data-on-rituxan-in-pv?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563858 Oct 14, 2019 - Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
Top Research Reports for Toyota, Amgen & TJX http://www.zacks.com/research-daily/559528/top-research-reports-for-toyota-amgen-tjx?cid=CS-ZC-FT-research_daily-559528 Oct 11, 2019 - Top Research Reports for Toyota, Amgen & TJX
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates http://www.zacks.com/stock/news/557902/3-big-drug-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=CS-ZC-FT-earnings_esp-557902 Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.

Pages: 1...4567891011121314...82

<<<Page 9>